{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:59:46Z","timestamp":1778767186025,"version":"3.51.4"},"reference-count":221,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Thrombocytopenia following hematopoietic stem cell transplantation (HSCT) is a common complication that is associated with a remarkable increase in morbidity and mortality. Post-HSCT thrombocytopenia is a multifactorial condition with several mechanisms, including reduced platelet production in bone marrow, immune-mediated platelet destruction, and consumptive thrombocytopenia. Graft-versus-host disease (GVHD), medications, infections, and autoimmune mechanisms are potential risk factors for post-HSCT thrombocytopenia. Management of post-HSCT thrombocytopenia primarily focuses on supportive care through platelet transfusions. Moreover, immunosuppressive agents are used to target immune-mediated mechanisms. Thrombopoietin receptor agonists and complement inhibitors are novel treatment options with promising results and fewer side effects. However, further research is essential to establish treatment protocols and improve patient care. In this review, we provide a better understanding of the pathophysiology and risk factors associated with post-HSCT thrombocytopenia for early detection and intervention, ultimately aiming to reduce complications.<\/jats:p>","DOI":"10.1055\/a-2673-4266","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T23:21:21Z","timestamp":1754090481000},"page":"106-125","source":"Crossref","is-referenced-by-count":2,"title":["Thrombocytopenia after Hematopoietic Stem Cell Transplantation in Pediatrics and Adults: A Narrative Review Including Etiology, Management, Monitoring, and Novel Therapies"],"prefix":"10.1055","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2629-1832","authenticated-orcid":false,"given":"Amirali","family":"Kalantari","sequence":"additional","affiliation":[{"name":"Pediatric Cell and Gene Therapy Research Center, Gene, Cell and Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9658-6354","authenticated-orcid":false,"given":"Zahra","family":"Karimizadeh","sequence":"additional","affiliation":[{"name":"Pediatric Cell and Gene Therapy Research Center, Gene, Cell and Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leila","family":"Jafari","sequence":"additional","affiliation":[{"name":"Pediatric Cell and Gene Therapy Research Center, Gene, Cell and Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Behfar","sequence":"additional","affiliation":[{"name":"Pediatric Cell and Gene Therapy Research Center, Gene, Cell and Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8935-079X","authenticated-orcid":false,"given":"Amir Ali","family":"Hamidieh","sequence":"additional","affiliation":[{"name":"Pediatric Cell and Gene Therapy Research Center, Gene, Cell and Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"issue":"04","key":"ref1","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/leu.2011.257","article-title":"Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study","volume":"26","author":"Z Kuzmina","year":"2012","journal-title":"Leukemia"},{"issue":"03","key":"ref2","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1053\/bbmt.2001.v7.pm11302549","article-title":"Secondary failure of platelet recovery after hematopoietic stem cell transplantation","volume":"7","author":"B Bruno","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"issue":"02","key":"ref3","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/blood.V65.2.368.368","article-title":"Isolated thrombocytopenia after allogeneic bone marrow transplantation: existence of transient and chronic thrombocytopenic syndromes","volume":"65","author":"L R First","year":"1985","journal-title":"Blood"},{"issue":"09","key":"ref4","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1182\/blood.V91.9.3509","article-title":"A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation","volume":"91","author":"S H Bernstein","year":"1998","journal-title":"Blood"},{"issue":"04","key":"ref5","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/sj.bmt.1704330","article-title":"Prognostic importance of the platelet count 100 days post allogeneic bone marrow transplant","volume":"33","author":"B Bolwell","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"02","key":"ref6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/trf.12817","article-title":"Impact of platelet transfusion on toxicity and mortality after hematopoietic progenitor cell transplantation","volume":"55","author":"G Christou","year":"2015","journal-title":"Transfusion"},{"issue":"08","key":"ref7","doi-asserted-by":"crossref","first-page":"e37250","DOI":"10.1097\/MD.0000000000037250","article-title":"Chemotherapy-associated hemorrhagic posterior reversible encephalopathy syndrome (PRES) with considerations for circle of Willis variants on cerebral blood flow and autoregulation: A case report","volume":"103","author":"B S Srichawla","year":"2024","journal-title":"Medicine (Baltimore)"},{"issue":"06","key":"ref8","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.12669\/pjms.316.8357","article-title":"Use of recombinant factor VIIa in uncontrolled gastrointestinal bleeding after hematopoietic stem cell transplantation among patients with thrombocytopenia","volume":"31","author":"Y Tang","year":"2015","journal-title":"Pak J Med Sci"},{"issue":"05","key":"ref9","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/sj.bmt.1702166","article-title":"Diagnosis and management of subdural haematoma complicating bone marrow transplantation","volume":"25","author":"M Colosimo","year":"2000","journal-title":"Bone Marrow Transplant"},{"issue":"06","key":"ref10","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1016\/j.chest.2021.01.008","article-title":"Epidemiology, risk factors, and outcomes of diffuse alveolar hemorrhage after hematopoietic stem cell transplantation","volume":"159","author":"Z Zhang","year":"2021","journal-title":"Chest"},{"issue":"12","key":"ref11","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1111\/trf.14315","article-title":"The first reported case of concurrent trimethoprim-sulfamethoxazole-induced immune hemolytic anemia and thrombocytopenia","volume":"57","author":"Y A Linnik","year":"2017","journal-title":"Transfusion"},{"issue":"03","key":"ref12","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/sj.bmt.1701888","article-title":"Immune thrombocytopenia after umbilical cord progenitor cell transplant: response to vincristine","volume":"24","author":"S Dovat","year":"1999","journal-title":"Bone Marrow Transplant"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"e2034750","DOI":"10.1001\/jamanetworkopen.2020.34750","article-title":"Evaluation of ruxolitinib for steroid-refractory chronic graft-vs-host disease after allogeneic hematopoietic stem cell transplantation","volume":"4","author":"H Wu","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"12","key":"ref14","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"A H Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"08","key":"ref15","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.bbmt.2020.03.024","article-title":"Incidence, risk factors, and outcomes of primary prolonged isolated thrombocytopenia after haploidentical hematopoietic stem cell transplant","volume":"26","author":"F F Tang","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1476-0711-6-16","article-title":"Infections caused by mycobacterium tuberculosis in patients with hematological disorders and in recipients of hematopoietic stem cell transplant, a twelve year retrospective study","volume":"6","author":"K A Al-Anazi","year":"2007","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"07","key":"ref17","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1086\/428060","article-title":"Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation","volume":"40","author":"D M Zerr","year":"2005","journal-title":"Clin Infect Dis"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"879994","DOI":"10.3389\/fimmu.2022.879994","article-title":"Autoimmune cytopenias post hematopoietic stem cell transplantation in pediatric patients with osteopetrosis and other nonmalignant diseases","volume":"13","author":"E Even-Or","year":"2022","journal-title":"Front Immunol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"940320","DOI":"10.3389\/fonc.2022.940320","article-title":"Prognostic value of thrombocytopenia in myelodysplastic syndromes after hematopoietic stem cell transplantation","volume":"12","author":"H Wang","year":"2022","journal-title":"Front Oncol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.critrevonc.2016.09.004","article-title":"An overview of hematopoietic stem cell transplantation related thrombotic complications","volume":"107","author":"U Sahin","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"109579","DOI":"10.1016\/j.intimp.2022.109579","article-title":"Low-dose decitabine for refractory thrombocytopenia following allogeneic hematopoietic stem cell transplantation in children: A pilot study","volume":"115","author":"N Liu","year":"2023","journal-title":"Int Immunopharmacol"},{"issue":"05","key":"ref22","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.3390\/jcm11051364","article-title":"Thrombocytopenia and therapeutic strategies after allogeneic hematopoietic stem cell transplantation","volume":"11","author":"L Bento","year":"2022","journal-title":"J Clin Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"564647","DOI":"10.3389\/fimmu.2020.564647","article-title":"Efficacy and safety of eculizumab in the treatment of transplant-associated thrombotic microangiopathy: a systematic review and meta-analysis","volume":"11","author":"R Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"101948","DOI":"10.1016\/j.trim.2023.101948","article-title":"Thrombopoietin receptor agonists for refractory thrombocytopenia in patients after autologous hematopoietic stem cell transplantation","volume":"81","author":"D Wang","year":"2023","journal-title":"Transpl Immunol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"910893","DOI":"10.3389\/fimmu.2022.910893","article-title":"Analysis of the efficacy and safety of avatrombopag combined with MSCs for the treatment of thrombocytopenia after allogeneic hematopoietic stem cell transplantation","volume":"13","author":"L Zhu","year":"2022","journal-title":"Front Immunol"},{"issue":"22","key":"ref26","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1200\/JCO.21.02389","article-title":"Narsoplimab, a mannan-binding lectin-associated serine protease-2 inhibitor, for the treatment of adult hematopoietic stem-cell transplantation-associated thrombotic microangiopathy","volume":"40","author":"S K Khaled","year":"2022","journal-title":"J Clin Oncol"},{"issue":"01","key":"ref27","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12916-022-02338-9","article-title":"Prophylactic NAC promoted hematopoietic reconstitution by improving endothelial cells after haploidentical HSCT: a phase 3, open-label randomized trial","volume":"20","author":"Y Wang","year":"2022","journal-title":"BMC Med"},{"key":"ref28","volume-title":"Nelson Essentials of Pediatrics. 9th ed","author":"K J Marcdante","year":"2023"},{"key":"ref29","volume-title":"Harrison's Principles of Internal Medicine. 21st ed","author":"J Loscalzo","year":"2022"},{"issue":"03","key":"ref30","first-page":"288","article-title":"Thrombocytopenia: evaluation and management","volume":"106","author":"R L Gauer","year":"2022","journal-title":"Am Fam Physician"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"101112","DOI":"10.1016\/j.blre.2023.101112","article-title":"Primary and secondary immune thrombocytopenia (ITP): time for a rethink","volume":"61","author":"T J Gonz\u00e1lez-L\u00f3pez","year":"2023","journal-title":"Blood Rev"},{"key":"ref32","first-page":"97","volume-title":"Chapter 7: BMT settings, infection and infection control","author":"J Murray","year":"2018"},{"issue":"03","key":"ref33","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1016\/j.bbmt.2019.12.003","article-title":"Use of thrombopoietin receptor agonists in prolonged thrombocytopenia after hematopoietic stem cell transplantation","volume":"26","author":"U Mahat","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"ref34","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/sj.bmt.1701499","article-title":"Prolonged isolated thrombocytopenia after hematopoietic stem cell transplantation: morphologic correlation","volume":"22","author":"M Bielski","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2147\/ITT.S463384","article-title":"Thrombopoietin receptor agonists in post-hematopoietic cell transplantation complicated by prolonged thrombocytopenia: a comprehensive review","volume":"13","author":"A Elsayed","year":"2024","journal-title":"ImmunoTargets Ther"},{"issue":"09","key":"ref36","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/j.bbmt.2019.05.036","article-title":"Incidence, risk factors, and outcomes of primary poor graft function after allogeneic hematopoietic stem cell transplantation","volume":"25","author":"Y Zhao","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"08","key":"ref37","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/s41409-019-0442-3","article-title":"Eltrombopag for post-transplant cytopenias due to poor graft function","volume":"54","author":"S Marotta","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"08","key":"ref38","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.bbmt.2014.04.015","article-title":"Association between an impaired bone marrow vascular microenvironment and prolonged isolated thrombocytopenia after allogeneic hematopoietic stem cell transplantation","volume":"20","author":"Y Kong","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"23","key":"ref39","doi-asserted-by":"crossref","first-page":"8497","DOI":"10.1002\/cam4.4353","article-title":"Haploidentical donor transplant is associated with secondary poor graft function after allogeneic stem cell transplantation: A single-center retrospective study","volume":"10","author":"W R Lv","year":"2021","journal-title":"Cancer Med"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"2040620720948743","DOI":"10.1177\/2040620720948743","article-title":"Advances in the understanding of poor graft function following allogeneic hematopoietic stem-cell transplantation","volume":"11","author":"J Chen","year":"2020","journal-title":"Ther Adv Hematol"},{"issue":"05","key":"ref41","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1007\/s12185-015-1821-1","article-title":"Romiplostim for secondary thrombocytopenia following allogeneic stem cell transplantation in children","volume":"102","author":"N Maximova","year":"2015","journal-title":"Int J Hematol"},{"issue":"04","key":"ref42","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1182\/blood-2012-03-418202","article-title":"A disease risk index for patients undergoing allogeneic stem cell transplantation","volume":"120","author":"P Armand","year":"2012","journal-title":"Blood"},{"issue":"04","key":"ref43","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1586\/ehm.10.32","article-title":"Relapse after allogeneic stem cell transplantation","volume":"3","author":"A J Barrett","year":"2010","journal-title":"Expert Rev Hematol"},{"key":"ref44","volume-title":"Chapter 41: Graft failure","author":"D Valc\u00e1rcel","year":"2024"},{"issue":"08","key":"ref45","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jtct.2021.04.007","article-title":"Standardizing definitions of hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the American Society for Transplantation and Cellular Therapy","volume":"27","author":"M A Kharfan-Dabaja","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"01","key":"ref46","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13287-024-03726-z","article-title":"Graft failure after allogeneic hematopoietic stem cell transplantation in pediatric patients with acute leukemia: autologous reconstitution or second transplant?","volume":"15","author":"T Rostami","year":"2024","journal-title":"Stem Cell Res Ther"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/978-3-642-54490-3_16","article-title":"Ruxolitinib","volume":"201","author":"H Becker","year":"2014","journal-title":"Recent Results Cancer Res"},{"issue":"12","key":"ref48","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1007\/s00277-023-05458-1","article-title":"Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were na\u00efve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial","volume":"102","author":"S Koschmieder","year":"2023","journal-title":"Ann Hematol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/978-3-319-91439-8_6","article-title":"Ruxolitinib","volume":"212","author":"S Ajayi","year":"2018","journal-title":"Recent Results Cancer Res"},{"issue":"01","key":"ref52","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s12185-024-03772-6","article-title":"Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial","volume":"120","author":"T Teshima","year":"2024","journal-title":"Int J Hematol"},{"issue":"05","key":"ref53","first-page":"544","article-title":"Impact of G-CSF administration post-allogeneic hematopoietic stem-cell transplantation on outcomes: a systematic review and meta-analysis","volume":"11","author":"A K Gupta","year":"2021","journal-title":"Am J Blood Res"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"113624","DOI":"10.1016\/j.bcp.2019.113624","article-title":"G-CSF administration results in thrombocytopenia by inhibiting the differentiation of hematopoietic progenitors into megakaryocytes","volume":"169","author":"Y Li","year":"2019","journal-title":"Biochem Pharmacol"},{"issue":"04","key":"ref56","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1172\/JCI116330","article-title":"Identification of a functional receptor for granulocyte colony-stimulating factor on platelets","volume":"91","author":"K Shimoda","year":"1993","journal-title":"J Clin Invest"},{"issue":"03","key":"ref57","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/bmt.2008.310","article-title":"G-CSF-induced thrombocytopenia in a healthy donor","volume":"43","author":"O Minelli","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"ref58","doi-asserted-by":"crossref","first-page":"e14786","DOI":"10.1097\/MD.0000000000014786","article-title":"G-CSF-induced severe thrombocytopenia in a healthy donor: A rare case report","volume":"98","author":"X Lu","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"09","key":"ref59","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1093\/jac\/dkw157","article-title":"ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients","volume":"71","author":"J Maertens","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"05","key":"ref60","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1016\/S1473-3099(23)00495-4","article-title":"Guidelines for the management of Toxoplasma gondii infection and disease in patients with haematological malignancies and after haematopoietic stem-cell transplantation: guidelines from the 9th European Conference on Infections in Leukaemia, 2022","volume":"24","author":"R Aerts","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"03","key":"ref61","doi-asserted-by":"crossref","first-page":"206.e1","DOI":"10.1016\/j.jtct.2022.12.004","article-title":"Risk factors and outcomes of nocardiosis in hematopoietic stem cell transplantation recipients","volume":"29","author":"Z A Yetmar","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"02","key":"ref62","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jiac.2023.09.030","article-title":"Sulfamethoxazole-trimethoprim for pneumocystis pneumonia prophylaxis, causes of discontinuation and thrombocytopenia observed during administration: A single-center retrospective study","volume":"30","author":"M Hashimoto","year":"2024","journal-title":"J Infect Chemother"},{"issue":"07","key":"ref63","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.3390\/jcm9072212","article-title":"Pathophysiology and diagnosis of drug-induced immune thrombocytopenia","volume":"9","author":"C Vayne","year":"2020","journal-title":"J Clin Med"},{"issue":"05","key":"ref64","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1177\/0897190014546099","article-title":"Drug-induced immune thrombocytopenia","volume":"27","author":"T Kam","year":"2014","journal-title":"J Pharm Pract"},{"issue":"06","key":"ref65","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/17474086.2016.1174571","article-title":"Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation","volume":"9","author":"E Maffini","year":"2016","journal-title":"Expert Rev Hematol"},{"issue":"03","key":"ref66","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jmii.2021.01.001","article-title":"Cytomegalovirus management after allogeneic hematopoietic stem cell transplantation: A mini-review","volume":"54","author":"C L Jerry Teng","year":"2021","journal-title":"J Microbiol Immunol Infect"},{"key":"ref67","volume-title":"Cytomegalovirus Infections","author":"M Gupta","year":"2025"},{"issue":"04","key":"ref68","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.bbmt.2017.12.782","article-title":"Risk factors, treatment, and immune dysregulation in autoimmune cytopenia after allogeneic hematopoietic stem cell transplantation in pediatric patients","volume":"24","author":"M D Kruizinga","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"ref69","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood.V75.10.1965.1965","article-title":"Preferential suppression of myelopoiesis in normal human bone marrow cells after in vitro challenge with human cytomegalovirus","volume":"75","author":"G K Sing","year":"1990","journal-title":"Blood"},{"issue":"14","key":"ref70","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood.2023023142","article-title":"Virus-reactive T cells expanded in aplastic anemia eliminate hematopoietic progenitor cells by molecular mimicry","volume":"143","author":"A Ben Hamza","year":"2024","journal-title":"Blood"},{"issue":"08","key":"ref71","first-page":"651","article-title":"[Prevalence of EBV infection in patients with allogeneic hematopoietic stem cell transplantation]","volume":"34","author":"T T Han","year":"2013","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"12","key":"ref72","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1016\/j.bbmt.2015.07.035","article-title":"Epstein-Barr virus-related post-transplantation lymphoproliferative disorder after unmanipulated human leukocyte antigen haploidentical hematopoietic stem cell transplantation: incidence, risk factors, treatment, and clinical outcomes","volume":"21","author":"L P Xu","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"01","key":"ref73","doi-asserted-by":"crossref","first-page":"e2013061","DOI":"10.4084\/mjhid.2013.061","article-title":"Tuberculosis in hematopoietic stem cell transplant recipients","volume":"5","author":"J F Ramos","year":"2013","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"04","key":"ref74","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/bmt.2010.155","article-title":"Pancytopenia and myeloid maturation arrest in an autologous stem cell transplant recipient","volume":"46","author":"F C Kuan","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"1258561","DOI":"10.3389\/fcimb.2023.1258561","article-title":"Rare tuberculosis in recipients of allogeneic hematopoietic stem cell transplantation successfully treated with contezolid-a typical case report and literature review","volume":"13","author":"J Li","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"issue":"01","key":"ref76","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12985-023-01980-w","article-title":"Human herpesvirus-6 in hematopoietic stem cell transplant recipients: a prospective cohort study in Egypt","volume":"20","author":"M ME Raouf","year":"2023","journal-title":"Virol J"},{"issue":"03","key":"ref77","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1365-2141.2009.07622.x","article-title":"HHV-6 DNA throughout the tissues of two stem cell transplant patients with chromosomally integrated HHV-6 and fatal CMV pneumonitis","volume":"145","author":"P Hubacek","year":"2009","journal-title":"Br J Haematol"},{"issue":"06","key":"ref78","first-page":"1113","article-title":"Monitoring human herpesvirus-6 in patients with autologous stem cell transplantation","volume":"28","author":"K Piukovics","year":"2014","journal-title":"In Vivo"},{"key":"ref79","first-page":"20","article-title":"Post-allogeneic hematopoietic stem cell transplantation viral reactivations and viremias: a focused review on human herpesvirus-6, BK virus and adenovirus","volume":"8","author":"X Wang","year":"2021","journal-title":"Ther Adv Infect Dis"},{"issue":"05","key":"ref80","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/cid\/cit358","article-title":"Human herpesvirus 6 (HHV-6) reactivation and HHV-6 encephalitis after allogeneic hematopoietic cell transplantation: a multicenter, prospective study","volume":"57","author":"M Ogata","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"02","key":"ref81","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.bbmt.2013.11.014","article-title":"Autoimmune hematological diseases after allogeneic hematopoietic stem cell transplantation in children: an Italian multicenter experience","volume":"20","author":"M Faraci","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"03","key":"ref82","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.hoc.2013.03.001","article-title":"Immune thrombocytopenia","volume":"27","author":"G Kistangari","year":"2013","journal-title":"Hematol Oncol Clin North Am"},{"issue":"06","key":"ref83","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1007\/s00431-023-04912-6","article-title":"Immune-mediated cytopenias (IMCs) after HSCT for pediatric non-malignant disorders: epidemiology, risk factors, pathogenesis, and treatment","volume":"182","author":"M Spadea","year":"2023","journal-title":"Eur J Pediatr"},{"issue":"06","key":"ref84","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1038\/s41409-020-01179-5","article-title":"Consensus opinion on immune-mediated cytopenias after hematopoietic cell transplant for inherited metabolic disorders","volume":"56","author":"A O Gupta","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"01","key":"ref85","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/j.bbmt.2011.10.024","article-title":"Complications of transplant for nonmalignant disorders: autoimmune cytopenias, opportunistic infections, and PTLD","volume":"18","author":"C C Dvorak","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"09","key":"ref86","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2217\/imt-2017-0135","article-title":"Antithymocyte globulin-induced hemolytic anemia and thrombocytopenia after kidney transplantation","volume":"10","author":"T de Nattes","year":"2018","journal-title":"Immunotherapy"},{"issue":"10","key":"ref87","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1111\/ajt.13316","article-title":"Mechanism of platelet activation and hypercoagulability by antithymocyte globulins (ATG)","volume":"15","author":"A Cumpelik","year":"2015","journal-title":"Am J Transplant"},{"issue":"04","key":"ref88","doi-asserted-by":"crossref","first-page":"e27569","DOI":"10.1002\/pbc.27569","article-title":"Autoimmune hemolytic anemia and immune thrombocytopenia following hematopoietic stem cell transplant: A critical review of the literature","volume":"66","author":"C E Neunert","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"01","key":"ref89","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1046\/j.1365-2141.2001.02468.x","article-title":"Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose","volume":"112","author":"A Dominietto","year":"2001","journal-title":"Br J Haematol"},{"issue":"10","key":"ref90","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1182\/blood.V78.10.2773.2773","article-title":"Effect of graft-versus-host disease on hematopoiesis after bone marrow transplantation in mice","volume":"78","author":"P J van Dijken","year":"1991","journal-title":"Blood"},{"issue":"03","key":"ref91","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/sj.bmt.1701890","article-title":"Thrombotic microangiopathy following allogeneic bone marrow transplantation","volume":"24","author":"H Takatsuka","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"ref92","volume-title":"Chapter 40: Bleeding and thrombotic complications","author":"R Shah","year":"2024"},{"issue":"09","key":"ref93","doi-asserted-by":"crossref","first-page":"e13371","DOI":"10.1111\/ctr.13371","article-title":"Transplant-associated thrombotic microangiopathy: Incidence, prognostic factors, morbidity, and mortality in allogeneic hematopoietic cell transplantation","volume":"32","author":"E Gavriilaki","year":"2018","journal-title":"Clin Transplant"},{"issue":"03","key":"ref94","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.blre.2014.11.001","article-title":"A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury","volume":"29","author":"S Jodele","year":"2015","journal-title":"Blood Rev"},{"key":"ref95","volume-title":"Pizzo and Poplack's Pediatric Oncology","author":"P A Pizzo","year":"2021","edition":"8th ed."},{"key":"ref96","doi-asserted-by":"crossref","first-page":"896034","DOI":"10.3389\/fimmu.2022.896034","article-title":"The incidence, outcomes, and risk factors of secondary poor graft function in haploidentical hematopoietic stem cell transplantation for acquired aplastic anemia","volume":"13","author":"F Lin","year":"2022","journal-title":"Front Immunol"},{"issue":"26","key":"ref97","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1182\/blood-2014-03-551630","article-title":"How I treat sinusoidal obstruction syndrome","volume":"123","author":"N Chao","year":"2014","journal-title":"Blood"},{"key":"ref98","volume-title":"Lanzkowsky's Manual of Pediatric Hematology And Oncology. 7th ed","author":"J D Fish","year":"2022"},{"issue":"07","key":"ref99","doi-asserted-by":"crossref","first-page":"e501","DOI":"10.1097\/MPH.0000000000002938","article-title":"Refractory thrombocytopenia is the earliest diagnostic criterion for sinusoidal obstruction syndrome in children","volume":"46","author":"F Consonni","year":"2024","journal-title":"J Pediatr Hematol Oncol"},{"issue":"03","key":"ref100","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/jha2.728","article-title":"Early diagnosis of sinusoidal obstruction syndrome after hematopoietic stem cell transplantation, with modified diagnostic criteria including refractory thrombocytopenia","volume":"4","author":"H Ichikawa","year":"2023","journal-title":"eJHaem"},{"issue":"08","key":"ref101","doi-asserted-by":"crossref","first-page":"e01446","DOI":"10.14309\/crj.0000000000001446","article-title":"Idiopathic multicentric castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis\/renal insufficiency, and organomegaly (TAFRO) syndrome in a liver transplant recipient","volume":"11","author":"F A Mashal","year":"2024","journal-title":"ACG Case Rep J"},{"issue":"03","key":"ref102","first-page":"e23688","article-title":"Post-transplant complication with TAFRO features in a patient with acute myeloid leukemia","volume":"14","author":"K Yamaguchi","year":"2022","journal-title":"Cureus"},{"issue":"01","key":"ref103","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2169\/internalmedicine.9622-22","article-title":"TAFRO syndrome: a disease requiring immediate medical attention","volume":"62","author":"Y Masaki","year":"2023","journal-title":"Intern Med"},{"issue":"04","key":"ref104","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3390\/biom14040489","article-title":"Thrombopoietin, the primary regulator of platelet production: from mythos to logos, a thirty-year journey","volume":"14","author":"K Kaushansky","year":"2024","journal-title":"Biomolecules"},{"issue":"09","key":"ref105","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1182\/blood.V88.9.3354.bloodjournal8893354","article-title":"Differential mechanisms in the regulation of endogenous levels of thrombopoietin and interleukin-11 during thrombocytopenia: insight into the regulation of platelet production","volume":"88","author":"M Chang","year":"1996","journal-title":"Blood"},{"issue":"02","key":"ref106","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/ctr.12673","article-title":"Characterization of thrombopoietin kinetics within 60 days after allogeneic hematopoietic stem cell transplantation and its correlation with megakaryocyte ploidy distribution","volume":"30","author":"H Fu","year":"2016","journal-title":"Clin Transplant"},{"issue":"02","key":"ref107","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.transci.2018.04.014","article-title":"Graft failure after allogeneic hematopoietic stem cell transplantation","volume":"57","author":"Z N Ozdemir","year":"2018","journal-title":"Transfus Apher Sci"},{"issue":"04","key":"ref108","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/bjh.13215","article-title":"How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation","volume":"168","author":"E Carreras","year":"2015","journal-title":"Br J Haematol"},{"issue":"07","key":"ref109","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.bbmt.2020.03.009","article-title":"Risk factors, clinical outcomes, and cost-of-care related to graft failure in pediatric allogeneic hematopoietic cell transplant recipients","volume":"26","author":"H Wobma","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"04","key":"ref110","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/bmt.2012.239","article-title":"Graft failure in the modern era of allogeneic hematopoietic SCT","volume":"48","author":"R Olsson","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"06","key":"ref111","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1538-7836.2009.03360.x","article-title":"Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management","volume":"7","author":"R H Aster","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref112","doi-asserted-by":"crossref","first-page":"309","DOI":"10.5858\/133.2.309","article-title":"Drug-induced thrombocytopenia","volume":"133","author":"B Kenney","year":"2009","journal-title":"Arch Pathol Lab Med"},{"issue":"06","key":"ref113","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s12185-016-1979-1","article-title":"Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version","volume":"103","author":"Y Masaki","year":"2016","journal-title":"Int J Hematol"},{"issue":"08","key":"ref114","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s00277-022-04862-3","article-title":"Relapse surveillance of acute myeloid leukemia patients in first remission after consolidation chemotherapy: diagnostic value of regular bone marrow aspirations","volume":"101","author":"S E Koschade","year":"2022","journal-title":"Ann Hematol"},{"key":"ref115","doi-asserted-by":"crossref","first-page":"217264","DOI":"10.1016\/j.canlet.2024.217264","article-title":"Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 update","volume":"605","author":"Y Wang","year":"2024","journal-title":"Cancer Lett"},{"key":"ref116","volume-title":"Chapter 57: Monitoring measurable residual disease in ALL and AML","author":"P Bader","year":"2024"},{"issue":"08","key":"ref117","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/sj.bmt.1702004","article-title":"A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim\/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation","volume":"24","author":"C Colby","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"ref118","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/ijlh.13954","article-title":"Diagnosis and treatment of thrombotic microangiopathy","volume":"44","author":"G L Thompson","year":"2022","journal-title":"Int J Lab Hematol"},{"issue":"11","key":"ref119","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1080\/17474086.2021.1995347","article-title":"Immune thrombocytopenia","volume":"14","author":"J Bussel","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"ref120","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejim.2022.11.022","article-title":"Current approaches for the diagnosis and management of immune thrombocytopenia","volume":"108","author":"A Gafter-Gvili","year":"2023","journal-title":"Eur J Intern Med"},{"issue":"01","key":"ref121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40121-017-0180-z","article-title":"Who is the patient at risk of CMV recurrence: a review of the current scientific evidence with a focus on hematopoietic cell transplantation","volume":"7","author":"J Styczynski","year":"2018","journal-title":"Infect Dis Ther"},{"issue":"14","key":"ref122","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.3390\/jcm10143034","article-title":"The syndromes of thrombotic microangiopathy: a critical appraisal on complement dysregulation","volume":"10","author":"S AMEG Timmermans","year":"2021","journal-title":"J Clin Med"},{"issue":"03","key":"ref123","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jtct.2022.11.015","article-title":"Harmonizing definitions for diagnostic criteria and prognostic assessment of transplantation-associated thrombotic microangiopathy: a report on behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research","volume":"29","author":"M L Schoettler","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"01","key":"ref124","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/pharmaceutics3010053","article-title":"Factors and mechanisms for pharmacokinetic differences between pediatric population and adults","volume":"3","author":"E Fernandez","year":"2011","journal-title":"Pharmaceutics"},{"issue":"04","key":"ref125","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s40262-023-01225-7","article-title":"Pharmacokinetics and pharmacodynamics of ruxolitinib: a review","volume":"62","author":"T YJ Appeldoorn","year":"2023","journal-title":"Clin Pharmacokinet"},{"issue":"01","key":"ref127","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.pcl.2009.11.003","article-title":"Chronic graft-versus-host disease (GVHD) in children","volume":"57","author":"K Baird","year":"2010","journal-title":"Pediatr Clin North Am"},{"issue":"01","key":"ref128","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2016-06-686618","article-title":"Chronic graft-versus-host disease: biological insights from preclinical and clinical studies","volume":"129","author":"K P MacDonald","year":"2017","journal-title":"Blood"},{"issue":"18","key":"ref129","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.3390\/cells13181524","article-title":"Current approaches for the prevention and treatment of acute and chronic GVHD","volume":"13","author":"A Olivieri","year":"2024","journal-title":"Cells"},{"issue":"12","key":"ref130","doi-asserted-by":"crossref","first-page":"e70059","DOI":"10.1002\/hem3.70059","article-title":"Definitions matter: Multicenter investigation of incidence and outcome of poor graft function after hematopoietic cell transplantation","volume":"8","author":"K F M\u00fcskens","year":"2024","journal-title":"HemaSphere"},{"issue":"08","key":"ref131","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.bbmt.2012.01.015","article-title":"A meta-analysis of unrelated donor umbilical cord blood transplantation versus unrelated donor bone marrow transplantation in acute leukemia patients","volume":"18","author":"H Zhang","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref132","volume-title":"Chapter 24: Transfusion support","author":"A Sureda","year":"2024"},{"key":"ref133","volume-title":"Platelet Transfusion","author":"A Agarwal","year":"2024"},{"issue":"01","key":"ref134","doi-asserted-by":"crossref","first-page":"128","DOI":"10.46989\/001c.94135","article-title":"Transfusion support in hematopoietic stem cell transplantation: a contemporary narrative review","volume":"6","author":"B D Adkins","year":"2024","journal-title":"Clin Hematol Int"},{"key":"ref135","doi-asserted-by":"crossref","first-page":"22","DOI":"10.21037\/aob-22-11","article-title":"Provision of human leukocyte antigen (HLA) selected platelets: 10-year experience of a regional blood centre","volume":"8","author":"L KL Chan","year":"2022","journal-title":"Ann Blood"},{"issue":"02","key":"ref136","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3109\/09537104.2014.895922","article-title":"Rituximab, plasma exchange and intravenous immunoglobulins as a new treatment strategy for severe HLA alloimmune platelet refractoriness","volume":"26","author":"J Cid","year":"2015","journal-title":"Platelets"},{"issue":"10","key":"ref137","doi-asserted-by":"crossref","first-page":"e013483","DOI":"10.1136\/bmjopen-2016-013483","article-title":"Rationale and design of platelet transfusions in haematopoietic stem cell transplantation: the PATH pilot study","volume":"6","author":"J Tay","year":"2016","journal-title":"BMJ Open"},{"issue":"09","key":"ref138","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/ajh.20958","article-title":"Hepatic veno-occlusive disease after tranexamic acid administration in patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"82","author":"T Mori","year":"2007","journal-title":"Am J Hematol"},{"issue":"02","key":"ref139","first-page":"103","article-title":"Eltrombopag for treatment of thrombocytopenia following hematopoietic stem cell transplantation","volume":"39","author":"Z T G\u00fcven","year":"2022","journal-title":"Turk J Haematol"},{"issue":"180","key":"ref140","first-page":"405","article-title":"[The use of IVIG in pediatric oncohematology and hematopoietic stem cell transplantation]","volume":"30","author":"K Kalwak","year":"2011","journal-title":"Pol Merkuriusz Lek"},{"issue":"01","key":"ref141","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40348-021-00114-y","article-title":"Daratumumab therapy for post-HSCT immune-mediated cytopenia: experiences from two pediatric cases and review of literature","volume":"8","author":"L Driouk","year":"2021","journal-title":"Mol Cell Pediatr"},{"issue":"10","key":"ref142","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1080\/10428194.2017.1421759","article-title":"Successful treatment of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation with bortezomib","volume":"59","author":"L Cao","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"ref143","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1002\/pbc.25172","article-title":"Bortezomib for effective treatment of a child with refractory autoimmune hemolytic anemia post allogeneic hematopoietic stem cell transplant","volume":"61","author":"B Mehta","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"01","key":"ref144","doi-asserted-by":"crossref","first-page":"e28010","DOI":"10.1002\/pbc.28010","article-title":"Successful treatment with daratumumab for post-HSCT refractory hemolytic anemia","volume":"67","author":"E Even-Or","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"03","key":"ref145","first-page":"e80274","article-title":"Successful treatment of TAFRO (thrombocytopenia, anasarca, fever, renal insufficiency, and organomegaly) syndrome with triple combination therapy of corticosteroid, tocilizumab, and cyclosporine: a case report","volume":"17","author":"J Morino","year":"2025","journal-title":"Cureus"},{"issue":"11","key":"ref146","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt1344","article-title":"Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"25","author":"R P Rother","year":"2007","journal-title":"Nat Biotechnol"},{"issue":"04","key":"ref147","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.bbmt.2013.12.565","article-title":"Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"20","author":"S Jodele","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"20","key":"ref148","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1182\/bloodadvances.2017008250","article-title":"In vitro evidence of complement activation in transplantation-associated thrombotic microangiopathy","volume":"1","author":"S J Rotz","year":"2017","journal-title":"Blood Adv"},{"issue":"01","key":"ref149","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/1076029615598221","article-title":"Hematopoietic stem cell transplant-associated thrombotic microangiopathy","volume":"22","author":"O Elsallabi","year":"2016","journal-title":"Clin Appl Thromb Hemost"},{"issue":"03","key":"ref150","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/jca.21352","article-title":"Outcomes of plasma exchange in patients with transplant-associated thrombotic microangiopathy based on time of presentation since transplant","volume":"30","author":"S Mulay","year":"2015","journal-title":"J Clin Apher"},{"issue":"03","key":"ref151","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1537-2995.2012.03776.x","article-title":"Does early initiation of therapeutic plasma exchange improve outcome in pediatric stem cell transplant-associated thrombotic microangiopathy?","volume":"53","author":"S Jodele","year":"2013","journal-title":"Transfusion"},{"issue":"11","key":"ref152","doi-asserted-by":"crossref","first-page":"764.e1","DOI":"10.1016\/j.jtct.2022.07.029","article-title":"N-acetylcysteine as prophylactic therapy for transplantation-associated thrombotic microangiopathy: a randomized, placebo-controlled trial","volume":"28","author":"T Pan","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"04","key":"ref153","doi-asserted-by":"crossref","first-page":"216.e1","DOI":"10.1016\/j.jtct.2021.12.018","article-title":"N-acetyl-L-cysteine potentially inhibits complement activation in transplantation-associated thrombotic microangiopathy","volume":"28","author":"J Qi","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"02","key":"ref154","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jamaoncol.2014.316","article-title":"Low-dose decitabine for patients with thrombocytopenia following allogeneic hematopoietic stem cell transplantation: a pilot therapeutic study","volume":"1","author":"Y Han","year":"2015","journal-title":"JAMA Oncol"},{"issue":"05","key":"ref155","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1182\/bloodadvances.2020002790","article-title":"Low-dose decitabine for refractory prolonged isolated thrombocytopenia after HCT: a randomized multicenter trial","volume":"5","author":"Y Tang","year":"2021","journal-title":"Blood Adv"},{"issue":"14","key":"ref156","first-page":"964","article-title":"[Donor peripheral stem cells infusion for the treatment of failure of platelet recovery after allogeneic hematopoietic stem cell transplantation]","volume":"87","author":"Y Chen","year":"2007","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"01","key":"ref157","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12185-013-1382-0","article-title":"The biology of thrombopoietin and thrombopoietin receptor agonists","volume":"98","author":"D J Kuter","year":"2013","journal-title":"Int J Hematol"},{"issue":"06","key":"ref158","doi-asserted-by":"crossref","first-page":"497.e1","DOI":"10.1016\/j.jtct.2021.02.033","article-title":"Phase I dose-finding, safety, and tolerability trial of romiplostim to improve platelet recovery after UCB transplantation","volume":"27","author":"G E Christakopoulos","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"07","key":"ref159","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.bbmt.2019.01.027","article-title":"Eltrombopag for treating thrombocytopenia after allogeneic stem cell transplantation","volume":"25","author":"C Yuan","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref160","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/20406207221127532","article-title":"Avatrombopag for the treatment of thrombocytopenia post hematopoietic stem-cell transplantation","volume":"13","author":"M Zhou","year":"2022","journal-title":"Ther Adv Hematol"},{"issue":"02","key":"ref161","doi-asserted-by":"crossref","first-page":"S423","DOI":"10.1016\/j.jtct.2023.12.606","article-title":"Avatrombopag safe and effective in treatment of severe refractory thrombocytopenia in a pediatric patient with Philadelphia chromosome positive acute lymphoblastic leukemia following allogeneic hematopoietic stem cell transplantation","volume":"30","author":"A Citta","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"ref162","doi-asserted-by":"crossref","first-page":"1099372","DOI":"10.3389\/fped.2023.1099372","article-title":"Avatrombopag for the treatment of thrombocytopenia in children's patients following allogeneic hematopoietic stem-cell transplantation: A pilot study","volume":"11","author":"Y Ruan","year":"2023","journal-title":"Front Pediatr"},{"issue":"01","key":"ref163","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41598-017-19099-8","article-title":"Eltrombopag versus romiplostim in treatment of children with persistent or chronic immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysis","volume":"8","author":"J Zhang","year":"2018","journal-title":"Sci Rep"},{"issue":"01","key":"ref164","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40360-025-00873-8","article-title":"Safety analysis of romiplostim, eltrombopag, and avatrombopag post-market approval: a pharmacovigilance study based on the FDA Adverse Event Reporting System","volume":"26","author":"X Wang","year":"2025","journal-title":"BMC Pharmacol Toxicol"},{"issue":"08","key":"ref165","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1080\/09537104.2018.1557613","article-title":"A novel recombinant human thrombopoietin for treating prolonged isolated thrombocytopenia after allogeneic stem cell transplantation","volume":"30","author":"Y Q Sun","year":"2019","journal-title":"Platelets"},{"issue":"11","key":"ref166","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1080\/17474086.2021.2009337","article-title":"Efficacy and safety of thrombopoietin receptor agonists in the treatment of thrombocytopenia after hematopoietic stem cell transplantation: a meta-analysis and systematic review","volume":"14","author":"Y Yao","year":"2021","journal-title":"Expert Rev Hematol"},{"issue":"01","key":"ref168","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1083-8791(00)70049-8","article-title":"A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation","volume":"6","author":"R A Nash","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref169","first-page":"10","article-title":"Efficacy of recombinant human thrombopoietin for the treatment of secondary failure of platelet recovery after allogeneic HSCT","volume":"28","author":"Y Cao","year":"2022","journal-title":"Clin Appl Thromb Hemost"},{"issue":"01","key":"ref170","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.blre.2014.01.001","article-title":"Advances in stem cell mobilization","volume":"28","author":"R K Hopman","year":"2014","journal-title":"Blood Rev"},{"issue":"01","key":"ref171","first-page":"78","article-title":"Optimizing stem cells mobilization strategies to ameliorate patient outcomes: a review of guide- lines and recommendations","volume":"11","author":"S Mohammadi","year":"2017","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"key":"ref172","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/asheducation-2003.1.419","article-title":"Stem cell mobilization","author":"M H Cottler-Fox","year":"2003","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"02","key":"ref173","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1055\/s-0044-1786006","article-title":"Analysis of factors affecting hematopoietic stem cell mobilization efficiency and early hematopoietic reconstruction indicators during autologous peripheral blood hematopoietic stem cell transplantation","volume":"11","author":"H Shi","year":"2024","journal-title":"Glob Med Genet"},{"issue":"03","key":"ref174","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1182\/blood-2014-02-514778","article-title":"Conditioning regimens for hematopoietic cell transplantation: one size does not fit all","volume":"124","author":"B Gyurkocza","year":"2014","journal-title":"Blood"},{"issue":"07","key":"ref175","doi-asserted-by":"crossref","first-page":"586","DOI":"10.3390\/cells13070586","article-title":"Stem cells collection and mobilization in adult autologous\/allogeneic transplantation: critical points and future challenges","volume":"13","author":"M Prisciandaro","year":"2024","journal-title":"Cells"},{"issue":"10","key":"ref176","doi-asserted-by":"crossref","first-page":"e0287863","DOI":"10.1371\/journal.pone.0287863","article-title":"GPC-100, a novel CXCR4 antagonist, improves in vivo hematopoietic cell mobilization when combined with propranolol","volume":"18","author":"D D Sukhtankar","year":"2023","journal-title":"PLoS One"},{"key":"ref177","doi-asserted-by":"crossref","first-page":"609116","DOI":"10.3389\/fmed.2021.609116","article-title":"YF-H-2015005, a CXCR4 antagonist, for the mobilization of hematopoietic stem cells in non-Hodgkin lymphoma patients: A randomized, controlled, phase 3 clinical trial","volume":"8","author":"W Liu","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"04","key":"ref178","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41591-023-02273-z","article-title":"Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial","volume":"29","author":"Z D Crees","year":"2023","journal-title":"Nat Med"},{"issue":"04","key":"ref179","first-page":"101","article-title":"Novel treatment for graft-versus-host disease","volume":"4","author":"Y Inamoto","year":"2021","journal-title":"Blood Cell Ther"},{"issue":"01","key":"ref180","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40259-020-00454-7","article-title":"Current and emerging targeted therapies for acute graft-versus-host disease","volume":"35","author":"S Kasikis","year":"2021","journal-title":"BioDrugs"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"9949961","DOI":"10.1155\/2023\/9949961","article-title":"Novel pharmacological treatment options of steroid-refractory graft-versus-host disease","volume":"2023","author":"I Kovalenko","year":"2023","journal-title":"Adv Hematol"},{"key":"ref182","doi-asserted-by":"crossref","first-page":"578314","DOI":"10.3389\/fimmu.2020.578314","article-title":"New approaches for the treatment of chronic graft-versus-host disease: current status and future directions","volume":"11","author":"N EB Saidu","year":"2020","journal-title":"Front Immunol"},{"issue":"09","key":"ref183","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.3390\/ph15091100","article-title":"Novel and promising strategies for therapy of post-transplant chronic GVHD","volume":"15","author":"I Kostareva","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"S 01","key":"ref184","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/stem.5530140734","article-title":"The problem of thrombocytopenia after hematopoietic stem cell transplantation","volume":"14","author":"R A Nash","year":"1996","journal-title":"Stem Cells"},{"issue":"07","key":"ref185","doi-asserted-by":"crossref","first-page":"e19096","DOI":"10.1097\/MD.0000000000019096","article-title":"Immature platelet fraction: A useful marker for identifying the cause of thrombocytopenia and predicting platelet recovery","volume":"99","author":"K Jeon","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"04","key":"ref186","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.pathol.2020.09.031","article-title":"Immature platelet fraction as a predictor of platelet count recovery following allogeneic bone marrow transplantation","volume":"53","author":"J Grabek","year":"2021","journal-title":"Pathology"},{"issue":"07","key":"ref187","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.pathol.2024.04.014","article-title":"Immature platelet fraction levels predict the development of prolonged thrombocytopenia after haematopoietic stem cell transplantation","volume":"56","author":"J Cao","year":"2024","journal-title":"Pathology"},{"issue":"01","key":"ref188","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3346\/jkms.2006.21.1.46","article-title":"Clinical significance of platelet count at day +60 after allogeneic peripheral blood stem cell transplantation","volume":"21","author":"D H Kim","year":"2006","journal-title":"J Korean Med Sci"},{"issue":"06","key":"ref189","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1634\/theoncologist.1-6-371","article-title":"The problem of thrombocytopenia after hematopoietic stem cell transplantation","volume":"1","author":"R A Nash","year":"1996","journal-title":"Oncologist"},{"key":"ref190","first-page":"S0887","article-title":"Autoimmune hemolytic anemia (AIHA) following allogeneic hematopoietic stem cell transplantation (HSCT): A retrospective analysis and a proposal of treatment on behalf of the Grupo Espanol De Trasplante de Medula Osea en Ninos (GETMON) and the Grupo Espanol de Trasplante Hematopoyetico (GETH)","author":"M Gonzalez-Vicent","year":"2018","journal-title":"Transfus Med Rev"},{"issue":"08","key":"ref191","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1038\/s41409-021-01283-0","article-title":"Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis","volume":"56","author":"J A Young","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"ref192","first-page":"6","article-title":"A narrative review of transplant-associated thrombotic microangiopathy: pathogenesis and novel therapies","volume":"8","author":"J Qi","year":"2023","journal-title":"Ann Blood"},{"issue":"11","key":"ref193","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1182\/blood.2022016308","article-title":"Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo-controlled, randomized clinical trial","volume":"140","author":"T B Gernsheimer","year":"2022","journal-title":"Blood"},{"key":"ref194","doi-asserted-by":"crossref","first-page":"103581","DOI":"10.1016\/j.critrevonc.2022.103581","article-title":"Risk of thrombosis with thrombopoietin receptor agonists for ITP patients: A systematic review and meta-analysis","volume":"171","author":"M Tjepkema","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"issue":"01","key":"ref195","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s12185-021-03218-3","article-title":"Incidence of refractory cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation","volume":"115","author":"F Jinnouchi","year":"2022","journal-title":"Int J Hematol"},{"issue":"02","key":"ref196","doi-asserted-by":"crossref","first-page":"106220","DOI":"10.1016\/j.jinf.2024.106220","article-title":"Real-world experience with letermovir for cytomegalovirus-prophylaxis after allogeneic hematopoietic cell transplantation: A multi-centre observational study","volume":"89","author":"S M Hopff","year":"2024","journal-title":"J Infect"},{"issue":"01","key":"ref197","first-page":"30","article-title":"Frequency of tuberculosis in haematological malignancies and stem cell transplant recipients","volume":"15","author":"B Khan","year":"2005","journal-title":"J Coll Physicians Surg Pak"},{"issue":"09","key":"ref198","first-page":"522","article-title":"Allogeneic peripheral blood stem cell transplantation in patients with haematological malignancies","volume":"14","author":"T S Shamsi","year":"2004","journal-title":"J Coll Physicians Surg Pak"},{"issue":"01","key":"ref199","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.athoracsur.2004.03.002","article-title":"Diffuse pulmonary infiltrates after bone marrow transplantation: the role of open lung biopsy","volume":"78","author":"J-Y Wang","year":"2004","journal-title":"Ann Thorac Surg"},{"issue":"05","key":"ref200","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/00007890-198311000-00008","article-title":"Mycobacterial infections in marrow transplant patients","volume":"36","author":"R M Navari","year":"1983","journal-title":"Transplantation"},{"issue":"05","key":"ref201","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/sj.bmt.1700686","article-title":"Mycobacterial infections following bone marrow transplantation: a 20 year retrospective review","volume":"19","author":"V Roy","year":"1997","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"ref202","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1038\/s41409-024-02398-w","article-title":"A systematic review and meta-analysis of HHV-6 and mortality after hematopoietic cell transplant","volume":"59","author":"C J Stathis","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"ref203","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1182\/blood-2023-178645","article-title":"Updated findings of a phase II study of ruxolitinib pre-, during-and post-hematopoietic stem cell transplantation for patients with primary or secondary myelofibrosis","volume":"142","author":"G S Hobbs","year":"2023","journal-title":"Blood"},{"issue":"02","key":"ref204","doi-asserted-by":"crossref","first-page":"e14466","DOI":"10.1111\/petr.14466","article-title":"Addition of ruxolitinib in Graft-versus-Host disease prophylaxis for pediatric \u03b2-thalassemia major patients after allogeneic stem cell transplantation: A retrospective cohort study","volume":"27","author":"X Hong","year":"2023","journal-title":"Pediatr Transplant"},{"issue":"12","key":"ref205","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1038\/bmt.2016.228","article-title":"Autoimmune hemolysis and immune thrombocytopenic purpura after cord blood transplantation may be life-threatening and warrants early therapy with rituximab","volume":"51","author":"V Bhatt","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"ref206","doi-asserted-by":"crossref","first-page":"1289180","DOI":"10.3389\/fmed.2023.1289180","article-title":"Peripheral blood stem cell transplantation vs. bone marrow transplantation for aplastic anemia: a systematic review and meta-analysis","volume":"10","author":"Z Zhang","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"12","key":"ref207","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.bbmt.2013.09.011","article-title":"Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation","volume":"19","author":"G Thanarajasingam","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"01","key":"ref208","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41409-020-00996-y","article-title":"GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia\/lymphoma","volume":"56","author":"H Muranushi","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"03","key":"ref209","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.bbmt.2019.09.022","article-title":"Relapse prevention with tyrosine kinase inhibitors after allogeneic transplantation for Philadelphia chromosome-positive acute lymphoblast leukemia: a systematic review","volume":"26","author":"Z Warraich","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"03","key":"ref210","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/leu.2013.253","article-title":"Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease","volume":"28","author":"V Bachanova","year":"2014","journal-title":"Leukemia"},{"issue":"01","key":"ref211","doi-asserted-by":"crossref","first-page":"32","DOI":"10.4103\/ijc.ijc_999_21","article-title":"Haploidentical stem cell transplantation in newly diagnosed high-risk neuroblastoma: Results from a single-arm, prospective study from India","volume":"62","author":"V V Swaminathan","year":"2025","journal-title":"Indian J Cancer"},{"issue":"05","key":"ref212","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/bmt.2010.187","article-title":"Cyclosporine levels and rate of graft rejection following non-myeloablative conditioning for allogeneic hematopoietic SCT","volume":"46","author":"S Gerull","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"06","key":"ref213","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/bmt.2017.5","article-title":"Changes in the incidence, patterns and outcomes of graft failure following hematopoietic stem cell transplantation for Hurler syndrome","volume":"52","author":"S H Lum","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"05","key":"ref214","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/bmt.2015.351","article-title":"Risk factors and outcome of graft failure after HLA matched and mismatched unrelated donor hematopoietic stem cell transplantation: a study on behalf of SFGM-TC and SFHI","volume":"51","author":"T Cluzeau","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"09","key":"ref215","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/bmt.2016.98","article-title":"Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis","volume":"51","author":"H Alchalby","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"ref216","doi-asserted-by":"crossref","first-page":"101076","DOI":"10.1016\/j.blre.2023.101076","article-title":"Definitions, incidence and outcome of poor graft function after hematopoietic cell transplantation: A systematic review and meta-analysis","volume":"60","author":"K F M\u00fcskens","year":"2023","journal-title":"Blood Rev"},{"issue":"05","key":"ref217","doi-asserted-by":"crossref","first-page":"266.e1","DOI":"10.1016\/j.jtct.2022.01.009","article-title":"Incidence and risk factors of transplantation-associated thrombotic microangiopathy: a systematic review and meta-analysis","volume":"28","author":"V Van Benschoten","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"03","key":"ref218","doi-asserted-by":"crossref","first-page":"S329","DOI":"10.1016\/j.bbmt.2017.12.387","article-title":"Incidence and mortality outcomes in allogeneic transplant-associated thrombotic microangiopathy","volume":"24","author":"M Sridharan","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"03","key":"ref219","first-page":"e23688","article-title":"Post-transplant Complication With TAFRO Features in a Patient With Acute Myeloid Leukemia","volume":"14","author":"K Yamaguchi","year":"2022","journal-title":"Cureus"},{"issue":"03","key":"ref220","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41409-019-0705-z","article-title":"Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a position statement from an international expert group","volume":"55","author":"M Mohty","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"04","key":"ref221","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/ajh.27233","article-title":"Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study","volume":"99","author":"S Ahmed","year":"2024","journal-title":"Am J Hematol"},{"issue":"08","key":"ref222","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1182\/bloodadvances.2022007838","article-title":"Open-label pilot study of romiplostim for thrombocytopenia after autologous hematopoietic cell transplantation","volume":"7","author":"M Scordo","year":"2023","journal-title":"Blood Adv"},{"issue":"11","key":"ref223","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/pbc.25122","article-title":"Treatment-refractory multi-lineage autoimmune cytopenia after unrelated cord blood transplantation: remission after combined bortezomib and vincristine treatment","volume":"61","author":"N Waespe","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"04","key":"ref224","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.hemonc.2019.05.006","article-title":"Bortezomib for immune thrombocytopenia and autoimmune hemolytic anemia","volume":"13","author":"I N Muhsen","year":"2020","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"05","key":"ref225","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1182\/bloodadvances.2019001215","article-title":"Successful treatment of thrombocytopenia with daratumumab after allogeneic transplant: a case report and literature review","volume":"4","author":"Y Migdady","year":"2020","journal-title":"Blood Adv"},{"issue":"08","key":"ref226","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/s41409-024-02305-3","article-title":"Safety and efficacy of narsoplimab in pediatric and adult patients with transplant-associated thrombotic microangiopathy: a real-world experience","volume":"59","author":"M Castelli","year":"2024","journal-title":"Bone Marrow Transplant"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2673-4266.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T23:35:34Z","timestamp":1768347334000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2673-4266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":221,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2026,1,13]]},"published-print":{"date-parts":[[2026,2]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2673-4266","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8,1]]},"published":{"date-parts":[[2025,8,1]]}}}